Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

November 14, 2012

Primary Completion Date

October 4, 2014

Study Completion Date

October 4, 2014

Conditions
Chronic Hepatitis B
Interventions
DRUG

Entecavir

DRUG

Myrcludex B

Trial Locations (9)

105275

"1-st MMU n.a. I.M. Sechenov based in Moscow State-Owned Health Care Institution Infectious Clinical Hospital № 2 of Moscow Healthcare Department", Moscow

117198

"FSBI of Higher Education People's Friendship University", Moscow

119333

"FSBHI Central Clinical Hospital RAS", Moscow

129110

"LLC Clinical Hospital of Tsentrosoyuz", Moscow

190103

"SPb SBHI The Center for Prevention and Control of AIDS and Infectious Diseases", Saint Petersburg

191167

"SPb SIH Clinical Centre of Infectious Diseases Named After S.P. Botkin", Saint Petersburg

355000

"SBIH Stavropol Regional Clinical Hospital", Stavropol

430063

"Medical Company Hepatolog LLC", Samara

454052

"SBEI of Higher Professional Education South Ural State Medical university of the MoH of the RF", Chelyabinsk

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Hepatera Ltd.

INDUSTRY

NCT02881008 - Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B | Biotech Hunter | Biotech Hunter